Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
North Chicago, Ill., September 26, 2025 – AbbVie (NYSE: ABBV) announced the submission of a New Drug Application (NDA)...
STAMFORD, CT, September 25, 2025 — Apiject Systems, Corp., a leading medical technology innovator, submitted its New Drug Application...
